Vigil Neuroscience, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.vigilneuro.com

Market Cap $92.42M
PE -1
Debt $NaN
Cash $45.82M
EV $NaN
FCF -$48.61M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$82.60M
EBIT	-$88.43M
ROE	-93%
ROA	-67%
FCF	-$48.61M
Equity	$88.55M
Growth Stability	1
PE	-1.12
PB	1.04
P/FCF	-1.9
Price/Cash	0.5
Equity CAGR	-26%
Earnings Growth YoY	-6%

Earnings Growth QoQ	-9%
Equity CAGR 5Y	-26%
Equity CAGR 3Y	-27%
Market Cap	$92.42M
Assets	$131.27M
Cash	$45.82M
Shares Outstanding	39.67M
Working Capital	83.14M
Current Ratio	3.72
Shares Growth 3y	17%
Equity Growth QoQ	4%
Equity Growth YoY	-35%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.

SEC Filings

Direct access to Vigil Neuroscience, Inc. (VIGL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vigil Neuroscience, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vigil Neuroscience, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vigil Neuroscience, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vigil Neuroscience, Inc..

Years

Calculation mode

= -$486M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$49M	-$486M
DCF		-$44M	-$40M	-$37M	-$33M	-$30M	-$27M	-$25M	-$23M	-$21M	-$19M	-$187M
Value	-$486M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-
ROA	-	-34%	-63%	-67%
ROE	-	-36%	-71%	-93%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-
Debt over Equity	-	-	-	-
Growth Stability	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-
Earnings YoY growth	-	58%	21%	-
Equity YoY growth	-	-372%	-39%	-26%
FCF YoY growth	-	67%	8%	-